Spero Therapeutics, Inc. (SPRO)

Market Cap	162.70M
Revenue (ttm)	44.58M
Net Income (ttm)	-69.76M
Shares Out	55.91M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	389,010
Open	2.900
Previous Close	2.900
Day's Range	2.900 - 2.940
52-Week Range	0.505 - 3.090
Beta	1.33
Analysts	Buy
Price Target	5.00 (+71.82%)
Earnings Date	Aug 4, 2025

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous my...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 2, 2017
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRO
• Website: https://sperotherapeutics.com

Analyst Summary

According to 4 analysts, the average rating for SPRO stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 71.82% from the latest price.

Price Target

$5.0

(71.82% upside)

Analyst Consensus: Buy